Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.

In a phase 2 trial, 156 adults with T2D, eGFR 30 to 75 ml/min per 1.73m 2 , with UACR 200 to 5000 mg/g on RAAS blockade were randomized 1:1:1 to placebo or praliciguat (20 or 40 mg), an sGC stimulator, with a placebo-adjusted UACR reduction of 15% that did not reach statistical significance. 87 In another phase 2 trial, the albuminuria lowering effects of avenciguat, an sGC activator, was evaluated in 500 patients with CKD (eGFR ≥ 20 and < 90 ml/min per 1.73m 2 and UACR ≥ 200 and < 3500 mg/g) with or without T2D. 88 At 20 weeks, placebo-corrected geometric mean changes from baseline i

also in 111,027 other papers